Search results
Results From The WOW.Com Content Network
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus , a region of the brain which is known to control appetite. [ 6 ]
Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn for agranulocytosis. [29] [30] [31] Levomethadyl acetate: 2003 US Cardiac arrhythmias and cardiac arrest. [2] Lorcaserin (Belviq) 2020 US Increased risk of ...
A category for drugs withdrawn from the market after marketing commenced for any reason (voluntarily or involuntarily). For drug candidates that were abandoned prior to being marketed due to side effects, lack of efficacy, superior competitors, or other reasons, see Category:Abandoned drugs
Science & Tech. Shopping. Sports
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a ...
An anorectic is a drug that reduces appetite, resulting in lower food consumption, leading to weight loss. [1] These substances work by affecting the central nervous system or certain neurotransmitters to create a feeling of fullness or reduce the desire to eat.
The U.S. Department of Education’s Office for Civil Rights has announced that it is rescinding all past guidance issued against the removal of books and will no longer employ a coordinator to ...
I'm well aware that lorcaserin is a touchy subject for investors. If the drug is approved, it's likely to be a gigantic money-maker just as fenfluramine was. Arena estimates that sales will net $1 billion per year. I believe this is the reason that the lorcaserin entry is being brutally edited.